Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Margitta Retz

Showing results (61-70 of 99) with videos related to

Pageof 10
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|June 19, 2016
Prospective evaluation of [<sup>11</sup>C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancerSarah M Schwarzenböck, Matthias Eiber, Günther Kundt, et al.
European Urology|November 27, 2018
Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with <sup>177</sup>Lu-PSMA-I&T in Metastatic Castration-resistant Prostate CancerMatthias M Heck, Robert Tauber, Sebastian Schwaiger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2018
Molecular Lymph Node Status for Prognostic Stratification of Prostate Cancer Patients Undergoing Radical Prostatectomy with Extended Pelvic Lymph Node DissectionMatthias M Heck, Margitta Retz, Miriam Bandur, et al.
BMC Medicine|August 23, 2015
A robust blood gene expression-based prognostic model for castration-resistant prostate cancerLi Wang, Yixuan Gong, Uma Chippada-Venkata, et al.
The Prostate|May 21, 2016
A 2-Gene Panel Derived From Prostate Cancer-Enhanced Transcripts in Whole Blood Is Prognostic for Survival and Predicts Treatment Benefit in Metastatic Castration-Resistant Prostate CancerMatthias M Heck, Mark Thalgott, Sebastian C Schmid, et al.
The Journal of Urology|March 12, 2016
Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate CancerMatthias M Heck, Margitta Retz, Calogero D'Alessandria, et al.
European Urology|March 8, 2013
Topography of lymph node metastases in prostate cancer patients undergoing radical prostatectomy and extended lymphadenectomy: results of a combined molecular and histopathologic mapping studyMatthias M Heck, Margitta Retz, Miriam Bandur, et al.
BMC Cancer|January 5, 2020
Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer - study protocol of a prospective, single arm, multicenter phase II trial (RACE IT)Sebastian C Schmid, Florestan J Koll, Claus Rödel, et al.
Infectious Agents and Cancer|September 23, 2015
Human papilloma virus is not detectable in samples of urothelial bladder cancer in a central European population: a prospective translational studySebastian C Schmid, Leonore Thümer, Tibor Schuster, et al.
Urologic Oncology|May 15, 2017
Wntless promotes bladder cancer growth and acts synergistically as a molecular target in combination with cisplatinSebastian C Schmid, Anuja Sathe, Ferdinand Guerth, et al.
Pageof 10

Showing results (61-70 of 99) with videos related to

Sort By:
Pageof 10
European Journal of Nuclear Medicine and Molecular Imaging|June 19, 2016
Prospective evaluation of [<sup>11</sup>C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancerSarah M Schwarzenböck, Matthias Eiber, Günther Kundt, et al.
European Urology|November 27, 2018
Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with <sup>177</sup>Lu-PSMA-I&T in Metastatic Castration-resistant Prostate CancerMatthias M Heck, Robert Tauber, Sebastian Schwaiger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2018
Molecular Lymph Node Status for Prognostic Stratification of Prostate Cancer Patients Undergoing Radical Prostatectomy with Extended Pelvic Lymph Node DissectionMatthias M Heck, Margitta Retz, Miriam Bandur, et al.
BMC Medicine|August 23, 2015
A robust blood gene expression-based prognostic model for castration-resistant prostate cancerLi Wang, Yixuan Gong, Uma Chippada-Venkata, et al.
The Prostate|May 21, 2016
A 2-Gene Panel Derived From Prostate Cancer-Enhanced Transcripts in Whole Blood Is Prognostic for Survival and Predicts Treatment Benefit in Metastatic Castration-Resistant Prostate CancerMatthias M Heck, Mark Thalgott, Sebastian C Schmid, et al.
The Journal of Urology|March 12, 2016
Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate CancerMatthias M Heck, Margitta Retz, Calogero D'Alessandria, et al.
European Urology|March 8, 2013
Topography of lymph node metastases in prostate cancer patients undergoing radical prostatectomy and extended lymphadenectomy: results of a combined molecular and histopathologic mapping studyMatthias M Heck, Margitta Retz, Miriam Bandur, et al.
BMC Cancer|January 5, 2020
Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer - study protocol of a prospective, single arm, multicenter phase II trial (RACE IT)Sebastian C Schmid, Florestan J Koll, Claus Rödel, et al.
Infectious Agents and Cancer|September 23, 2015
Human papilloma virus is not detectable in samples of urothelial bladder cancer in a central European population: a prospective translational studySebastian C Schmid, Leonore Thümer, Tibor Schuster, et al.
Urologic Oncology|May 15, 2017
Wntless promotes bladder cancer growth and acts synergistically as a molecular target in combination with cisplatinSebastian C Schmid, Anuja Sathe, Ferdinand Guerth, et al.
Pageof 10